Graham Capital Management’s Cogent Biosciences COGT Stock Holding History

Graham Capital Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,418	Closed	-$263K	–	1215
2025 Q4	$263K	Sell	7,418 -17,062	-70%	-$480K	0.01%	920
2025 Q3	$352K	Buy	24,480 +13,152	+116%	+$156K	0.01%	776
2025 Q2	$81.3K	Sell	11,328 -62,665	-85%	-$347K	﹤0.01%	1224
2025 Q1	$443K	Buy	+73,993	New	+$580K	0.01%	861
2024 Q3	–	Sell	-23,101	Closed	-$195K	–	1131
2024 Q2	$195K	Sell	23,101 -6,567	-22%	-$49.8K	﹤0.01%	872
2024 Q1	$199K	Buy	29,668 +1,926	+7%	+$11.9K	﹤0.01%	900
2023 Q4	$163K	Buy	+27,742	New	+$213K	﹤0.01%	867

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Graham Capital Management's COGT Position: Q1 2026 in Review

Graham Capital Management sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 7,418 shares — an estimated $263K sold.

Graham Capital Management first reported a position in COGT in Q4 2023 and held it in 7 quarters. The position peaked at $443K in Q1 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Graham Capital Management reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
Graham Capital Management sold 7,418 Cogent Biosciences shares in Q1 2026, an estimated $263K.
Graham Capital Management first reported a position in Cogent Biosciences in Q4 2023 and held it in 7 quarters.
Graham Capital Management's Cogent Biosciences position peaked at $443K in Q1 2025.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.